(Q37790485)

23 August 2017

title

A decade of progress in the discovery and development of 'atypical' antipsychotics (English)

1 reference

23 August 2017

Gregor J MacDonald

1

1 reference

23 August 2017

José Manuel Bartolomé

series ordinal

2

1 reference

23 August 2017

language of work or name

1 reference

1 January 2010

1 reference

Progress in medicinal chemistry

23 August 2017

published in

1 reference

23 August 2017

volume

49

1 reference

23 August 2017

page(s)

37-80

1 reference

Use of reserpine in disturbed psychotic patients.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Atypical antipsychotics: are some more atypical than others?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The role of serotonin in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Limbic selectivity of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Opinion: NK3 receptor antagonists: the next generation of antipsychotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Letter: Clozapine and agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Risperidone (Risperdal): clinical experience with a new antipsychosis drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Quetiapine. A review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Ziprasidone in the management of schizophrenia : the QT interval issue in context

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Do we need another atypical antipsychotic?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Sertindole: efficacy and safety in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

1 reference

7 January 2021

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Asenapine effects in animal models of psychosis and cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Blonanserin: a review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison with haloperidol, clozapine and risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

1 reference

7 January 2021

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Lurasidone: a new drug in development for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The dissociation rate of unlabelled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Current and Future Perspectives in Psychiatric Drug Discovery.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Schizophrenia: from dopamine to glutamate and back

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Dopamine D3 receptor antagonists as therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The neurobiology and control of anxious states

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Amisulpride: a review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Amisulpride is an "atypical" antipsychotic associated with low weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

How does the benzamide antipsychotic amisulpride get into the brain?--An in vitro approach comparing amisulpride with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Targeting the dopamine D2 receptor in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functio

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiologic

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Studies towards the identification of a new generation of atypical antipsychotic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effects of ketamine in normal and schizophrenic volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacological agents acting at subtypes of metabotropic glutamate receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Glutamatergic animal models of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Schizophrenia drug says goodbye to dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Synapse structure: glutamate receptors connected by the shanks

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Schizophrenia: moving beyond monoamine antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

The mammalian tachykinin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Tachykinins and tachykinin receptors: structure and activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

Adverse effects of antipsychotic agents. Do newer agents offer advantages?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2810%2949002-5

7 January 2021

10.1016/S0079-6468(10)49002-5

Identifiers

DOI

1 reference

23 August 2017

1 reference